Ameriprise’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-40,705
Closed -$608K 4090
2022
Q4
$608K Sell
40,705
-117,987
-74% -$1.63M ﹤0.01% 3328
2022
Q3
$1.31M Sell
158,692
-3,708
-2% -$28.5K ﹤0.01% 2983
2022
Q2
$1.06M Buy
+162,400
New +$787K ﹤0.01% 3093
2020
Q4
Sell
-39,640
Closed -$235K 3904
2020
Q3
$235K Buy
+39,640
New +$196K ﹤0.01% 3492
2014
Q4
Sell
-50
Closed -$1K 4696
2014
Q3
$1K Sell
50
-146
-74% -$1.86K ﹤0.01% 5630
2014
Q2
$4K Buy
196
+146
+292% +$1.9K ﹤0.01% 5029
2014
Q1
$1K Hold
50
﹤0.01% 5214
2013
Q4
$1K Sell
50
-323
-87% -$6.47K ﹤0.01% 5032
2013
Q3
$8K Hold
373
﹤0.01% 5050
2013
Q2
$9K Buy
+373
New +$15.9K ﹤0.01% 4871

Ameriprise's AVEO Position: Q1 2023 in Review

Ameriprise sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 40,705 shares — an estimated $608K sold.

Ameriprise first reported a position in AVEO in Q2 2013 and held it in 10 quarters. The position peaked at $1.31M in Q3 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Ameriprise reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Ameriprise sold 40,705 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $608K.
  • Ameriprise first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
  • Ameriprise's AVEO Pharmaceuticals, Inc. position peaked at $1.31M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Ameriprise's 13F filing for Q1 2023, filed 15 May 2023.